Ultimately, the rationally-designed GlueTAC achieved efficient degradation of cellular PD-L1 and demonstrated superior antitumor activity in the PD-L1-EGFP/A375 tumor model even compared with Atezolizumab, an FDA-approved anti-PD-L1 antibody. The gene discussed is CD274; the disease is neoplasm.